Research progress of gastric intestinal metaplasia

HUANG Qian; LI Xueliang

doi:10.7619/jcmp.20210403

Journal of Clinical Medicine in Practice > 2021 > 25(9): 107-112. > DOI: 10.7619/jcmp.20210403

HUANG Qian, LI Xueliang. Research progress of gastric intestinal metaplasia[J]. Journal of Clinical Medicine in Practice, 2021, 25(9): 107-112. DOI: 10.7619/jcmp.20210403

Citation:

HUANG Qian, LI Xueliang. Research progress of gastric intestinal metaplasia[J]. Journal of Clinical Medicine in Practice, 2021, 25(9): 107-112. DOI: 10.7619/jcmp.20210403

Citation:

HUANG Qian, LI Xueliang. Research progress of gastric intestinal metaplasia[J]. Journal of Clinical Medicine in Practice, 2021, 25(9): 107-112. DOI: 10.7619/jcmp.20210403

PDF (704 KB)

Research progress of gastric intestinal metaplasia

HUANG Qian,
LI Xueliang^,

Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029

More Information

Received Date: January 20, 2021
Available Online: May 20, 2021
Published Date: May 14, 2021

Graphical Abstract

Abstract

Abstract

Gastric intestinal metaplasia (IM) a pathomorphologic change in which gastric mucosal epithelial cells are replaced by intestinal epithelial cells. IM is widely regarded as the precursor of gastric cancer (especially intestinal gastric cancer) and has attracted wide attention. In recent years, scholars at home and abroad have conducted a large number of studies on the organizational characteristics, pathogenic factors and mechanisms, detection, diagnosis and treatment of IM. This paper reviewed the research progress of IM in the above aspects, aiming to deepen the clinical understanding of IM, and provide reference for the monitoring and prevention of IM and early gastric cancer.
- intestinal metaplasia,
- pathogenic factors and mechanisms,
- surveillance,
- early gastric cancer

FullText(HTML)

References (58)

References

[1]	SHAO L, LI P, YE J, et al. Risk of gastric cancer among patients with gastric intestinal Metaplasia[J]. Int J Cancer, 2018, 143(7): 1671-1677. doi: 10.1002/ijc.31571
[2]	LI D, BAUTISTA M C, JIANG S F, et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal Metaplasia and dysplasia: a population-based study[J]. Am J Gastroenterol, 2016, 111(8): 1104-1113. doi: 10.1038/ajg.2016.188
[3]	KINOSHITA H, HAYAKAWA Y, KOIKE K. Metaplasia in the stomach-precursor of gastric cancer?[J]. Int J Mol Sci, 2017, 18(10): E2063. doi: 10.3390/ijms18102063
[4]	HEILMANN K L, HÖPKER W W. Loss of differentiation in intestinal Metaplasia in cancerous stomachs. A comparative morphologic study[J]. Pathol Res Pract, 1979, 164(3): 249-258. doi: 10.1016/S0344-0338(79)80047-3
[5]	FILIPE M I, MUÑOZ N, MATKO I, et al. Intestinal Metaplasia types and the risk of gastric cancer: a cohort study in Slovenia[J]. Int J Cancer, 1994, 57(3): 324-329. doi: 10.1002/ijc.2910570306
[6]	SHIOTANI A, IISHI H, ISHIGURO S, et al. Epithelial cell turnover in relation to ongoing damage of the gastric mucosa in patients with early gastric cancer: increase of cell proliferation in paramalignant lesions[J]. J Gastroenterol, 2005, 40(4): 337-344. doi: 10.1007/s00535-004-1549-9
[7]	GONZÁLEZ C A, Sanz-Anquela J M, Companioni O, et al. Incomplete type of intestinal Metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study[J]. J Gastroenterol Hepatol, 2016, 31(5): 953-958. doi: 10.1111/jgh.13249
[8]	BLANKFIELD R P. Helicobacter pylori infection and the development of gastric cancer[J]. N Engl J Med, 2002, 346(1): 65-67. doi: 10.1056/NEJM200201033460115
[9]	CORREA P, SHIAO Y H. Phenotypic and genotypic events in gastric carcinogenesis[J]. Cancer Res, 1994, 54(7 Suppl): 1941s-1943s. http://carcin.oxfordjournals.org/lookup/ijlink?linkType=ABST&journalCode=canres&resid=54/7_Supplement/1941s
[10]	CORREA P. Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention[J]. Cancer Res, 1992, 52(24): 6735-6740. http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=canres&resid=52/24/6735
[11]	SHAH S C, GAWRON A J, MUSTAFA R A, et al. Histologic subtyping of gastric intestinal metaplasia: overview and considerations for clinical practice[J]. Gastroenterology, 2020, 158(3): 745-750. doi: 10.1053/j.gastro.2019.12.004
[12]	HÖCKER M, HOHENBERGER P. Helicobacter pylori virulence factors: one part of a big picture[J]. Lancet, 2003, 362(9391): 1231-1233. doi: 10.1016/S0140-6736(03)14547-3
[13]	PALFRAMAN S L, KWOK T, GABRIEL K. Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis[J]. Front Cell Infect Microbiol, 2012, 2: 92. http://www.ncbi.nlm.nih.gov/pubmed/22919683
[14]	WANG J, XU L J, SHI R H, et al. Gastric atrophy and intestinal Metaplasia before and after Helicobacter pylori eradication: a meta-analysis[J]. Digestion, 2011, 83(4): 253-260. doi: 10.1159/000280318
[15]	KODAMA M, MURAKAMI K, OKIMOTO T, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication[J]. J Gastroenterol, 2012, 47(4): 394-403. doi: 10.1007/s00535-011-0504-9
[16]	ZULLO A, RINALDI V, HASSAN C, et al. Ascorbic acid and intestinal Metaplasia in the stomach: a prospective, randomized study[J]. Aliment Pharmacol Ther, 2000, 14(10): 1303-1309. doi: 10.1046/j.1365-2036.2000.00841.x
[17]	KONG Y J, YI H G, DAI J C, et al. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis[J]. World J Gastroenterol, 2014, 20(19): 5903-5911. doi: 10.3748/wjg.v20.i19.5903
[18]	IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking[J]. IARC Monogr Eval Carcinog Risks Humans, 2004, 83: 1-1438. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=15285078
[19]	KIM K, CHANG Y, AHN J, et al. Smoking and urinary cotinine levels are predictors of increased risk for gastric intestinal Metaplasia[J]. Cancer Res, 2019, 79(3): 676-684. doi: 10.1158/0008-5472.CAN-18-2268
[20]	SNIR Y, VILKIN A, GINGOLD-BELFER R, et al. Sa1240 proton pump inhibitors use, HELICOBACTER pylori infection, anti parietal cell antibodies and smoking are associated with diagnosis of gastric intestinal METAPLASIA[J]. Gastrointest Endosc, 2018, 87(6): AB178. http://www.sciencedirect.com/science/article/pii/S0016510718305534
[21]	LEE S A, KANG D, SHIM K N, et al. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer[J]. J Epidemiol, 2003, 13(3): 162-168. doi: 10.2188/jea.13.162
[22]	SONG J H, KIM Y S, HEO N J, et al. High salt intake is associated with atrophic gastritis with intestinal Metaplasia[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(7): 1133-1138. doi: 10.1158/1055-9965.EPI-16-1024
[23]	SINGH K, GANDHI S, BATOOL R. A case-control study of the association between vitamin D levels and gastric incomplete intestinal Metaplasia[J]. Nutrients, 2018, 10(5): E629. doi: 10.3390/nu10050629
[24]	TAKAHASHI M, NISHIKAWA A, FURUKAWA F, et al. Dose-dependent promoting effects of sodium chloride (NaCI) on rat glandular stomach carcinogenesis initiated with Nmethyl-N'-nitro-N-nitrosoguanidine[J]. Carcinogenesis, 1994, 15(7): 1429-1432. doi: 10.1093/carcin/15.7.1429
[25]	CROSS A J, POLLOCK J R, BINGHAM S A. Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat[J]. Cancer Res, 2003, 63(10): 2358-2360. http://europepmc.org/abstract/MED/12750250
[26]	TATSUGAMI M, ITO M, TANAKA S, et al. Bile acid promotes intestinal Metaplasia and gastric carcinogenesis[J]. Cancer Epidemiol Biomarkers Prev, 2012, 21(11): 2101-2107. doi: 10.1158/1055-9965.EPI-12-0730
[27]	MINALYAN A, BENHAMMOU J N, ARTASHESYAN A, et al. Autoimmune atrophic gastritis: current perspectives[J]. Clin Exp Gastroenterol, 2017, 10: 19-27. doi: 10.2147/CEG.S109123
[28]	NIKOU G C, ANGELOPOULOS T P. Current concepts on gastric carcinoid tumors[J]. Gastroenterol Res Pract, 2012, 2012: 287825. http://europepmc.org/articles/pmc3534241/
[29]	KIM K, CHANG Y, AHN J, et al. Body mass index and risk of intestinal metaplasia: a cohort study[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(4): 789-797. doi: 10.1158/1055-9965.EPI-18-0733
[30]	CHOI S I, YOON C, PARK M R, et al. CDX1 expression induced by CagA-expressing Helicobacter pylori promotes gastric tumorigenesis[J]. Mol Cancer Res, 2019, 17(11): 2169-2183. doi: 10.1158/1541-7786.MCR-19-0181
[31]	ASANO N, IMATANI A, WATANABE T, et al. Cdx2 expression and intestinal Metaplasia induced by H. pylori infection of gastric cells is regulated by NOD1-mediated innate immune responses[J]. Cancer Res, 2016, 76(5): 1135-1145. doi: 10.1158/0008-5472.CAN-15-2272
[32]	YU J H, ZHENG J B, QI J, et al. Bile acids promote gastric intestinal Metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway[J]. Int J Oncol, 2019, 54(3): 879-892. http://www.researchgate.net/publication/330551295_Bile_acids_promote_gastric_intestinal_metaplasia_by_upregulating_CDX2_and_MUC2_expression_via_the_FXRNF-kB_signalling_pathway
[33]	LI T, GUO H Q, LI H, et al. MicroRNA-92a-1-5p increases CDX2 by targeting FOXD1 in bile acids-induced gastric intestinal Metaplasia[J]. Gut, 2019, 68(10): 1751-1763. doi: 10.1136/gutjnl-2017-315318
[34]	CAMILO V, GARRIDO M, VALENTE P, et al. Differentiation reprogramming in gastric intestinal Metaplasia and dysplasia: role of SOX2 and CDX2[J]. Histopathology, 2015, 66(3): 343-350. doi: 10.1111/his.12544
[35]	TSUKAMOTO T, INADA K, TANAKA H, et al. Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal Metaplasia[J]. J Cancer Res Clin Oncol, 2004, 130(3): 135-145. doi: 10.1007/s00432-003-0519-6
[36]	NIU H J, JIA Y C, LI T, et al. SOX2 inhibition promotes promoter demethylation of CDX2 to facilitate gastric intestinal Metaplasia[J]. Dig Dis Sci, 2017, 62(1): 124-132. doi: 10.1007/s10620-016-4361-5
[37]	YUAN T, NI Z, HAN C, et al. SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal Metaplasia[J]. Cancer Cell Int, 2019, 19: 24. doi: 10.1186/s12935-019-0739-8
[38]	LU W Q, NI Z, TONG M F, et al. DKK1 is epigenetically downregulated by promoter methylation and inhibits bile acid-induced gastric intestinal Metaplasia[J]. Biochem Biophys Res Commun, 2020, 523(3): 780-786. doi: 10.1016/j.bbrc.2019.12.109
[39]	HAMEDI ASL D, NASERPOUR FARIVAR T, RAHMANI B, et al. The role of transferrin receptor in the Helicobacter pylori pathogenesis; L-ferritin as a novel marker for intestinal Metaplasia[J]. Microb Pathog, 2019, 126: 157-164. doi: 10.1016/j.micpath.2018.10.039
[40]	DUAN X J, LIAN H W, LI J, et al. Expression of GCRG213p, LINE-1 endonuclease variant, significantly different in gastric complete and incomplete intestinal Metaplasia[J]. Diagn Pathol, 2019, 14(1): 61. doi: 10.1186/s13000-019-0838-9
[41]	FUKUDA H, MIURA Y, OSAWA, et al. Linked color imaging can enhance recognition of early gastric cancer by high color contrast to surrounding gastric intestinal Metaplasia[J]. J Gastroenterol, 2019, 54(5): 396-406. doi: 10.1007/s00535-018-1515-6
[42]	CHEN H L, WANG H S, WU X B, et al. Predictability of gastric intestinal Metaplasia by patchy lavender color seen on linked color imaging endoscopy[J]. Lasers Med Sci, 2019, 34(9): 1791-1797. doi: 10.1007/s10103-019-02775-8
[43]	ONO S, KATO M, TSUDA M, et al. Lavender color in linked color imaging enables noninvasive detection of gastric intestinal Metaplasia[J]. Digestion, 2018, 98(4): 222-230. doi: 10.1159/000489454
[44]	CHEN H L, LIU Y N, LU Y, et al. Ability of blue laser imaging with magnifying endoscopy for the diagnosis of gastric intestinal Metaplasia[J]. Lasers Med Sci, 2018, 33(8): 1757-1762. doi: 10.1007/s10103-018-2536-3
[45]	CHEN H L, WU X B, LIU Y N, et al. Blue laser imaging with acetic acid enhancement improved the detection rate of gastric intestinal Metaplasia[J]. Lasers Med Sci, 2019, 34(3): 555-559. doi: 10.1007/s10103-018-2629-z
[46]	SONG K H, HWANG J A, KIM S M, et al. Acetic acid chromoendoscopy for determining the extent of gastric intestinal Metaplasia[J]. Gastrointest Endosc, 2017, 85(2): 349-356. doi: 10.1016/j.gie.2016.07.064
[47]	LI L H, KANG D Y, TU H H, et al. Nonlinear optical microscopy for label-freely detecting gastric intestinal Metaplasia[J]. Laser Phys Lett, 2019, 16(1): 015602. doi: 10.1088/1612-202X/aaea72
[48]	CASTRO R, ESPOSITO G, LIBÂNIO D, et al. A single vial is enough in the absence of endoscopic suspected intestinal Metaplasia-less is more![J]. Scand J Gastroenterol, 2019, 54(5): 673-677. doi: 10.1080/00365521.2019.1613443
[49]	KUTLUANA U, KILCILER A G, MIZRAK S, et al. Can neopterin be a useful immune biomarker for differentiating gastric intestinal Metaplasia and gastric atrophy from non-atrophic non-metaplastic chronic gastritis?[J]. Gastroenterol Hepatol, 2019, 42(5): 289-295. doi: 10.1016/j.gastrohep.2019.01.005
[50]	PLUMMER M, FRANCESCHI S, VIGNAT J, et al. Global burden of gastric cancer attributable to Helicobacter pylori[J]. Int J Cancer, 2015, 136(2): 487-490. doi: 10.1002/ijc.28999
[51]	GUPTA S, LI D, EL SERAG H B, et al. AGA clinical practice guidelines on management of gastric intestinal Metaplasia[J]. Gastroenterology, 2020, 158(3): 693-702. doi: 10.1053/j.gastro.2019.12.003
[52]	DINIS-RIBEIRO M, KUIPERS E J. How to manage a patient with gastric intestinal metaplasia: an international perspective[J]. Gastroenterology, 2020, 158(6): 1534-1537. doi: 10.1053/j.gastro.2020.01.008
[53]	PIMENTEL-NUNES P, LIBÂNIO D, MARCOS-PINTO R, et al. Management of epithelial precancerous conditions and lesions in the stomach (maps ii): European society of gastrointestinal endoscopy (esge), European Helicobacter and microbiota study group (ehmsg), European society of pathology (esp), and sociedade portuguesa de endoscopia digestiva (sped) guideline update 2019[J]. Endoscopy, 2019, 51(4): 365-388. doi: 10.1055/a-0859-1883
[54]	BANKS M, GRAHAM D, JANSEN M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma[J]. Gut, 2019, 68(9): 1545-1575. doi: 10.1136/gutjnl-2018-318126
[55]	PIMENTA-MELO A R, MONTEIRO-SOARES M, LIBÂNIO D, et al. Missing rate for gastric cancer during upper gastrointestinal endoscopy[J]. Eur J Gastroenterol Hepatol, 2016, 28(9): 1041-1049. doi: 10.1097/MEG.0000000000000657
[56]	KANTSEVOY S V, ADLER D G, CONWAY J D, et al. Endoscopic mucosal resection and endoscopic submucosal dissection[J]. Gastrointest Endosc, 2008, 68(1): 11-18. doi: 10.1016/j.gie.2008.01.037
[57]	ONO H, YAO K S, FUJISHIRO M, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer[J]. Dig Endosc, 2016, 28(1): 3-15. doi: 10.1111/den.12518
[58]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492

[1]	DING Xiaorui, LU Minmin, DONG Hao. Effect and mechanism of N-acetylcysteine on methylnitrosourea-induced precancerous lesions of gastric cancer[J]. Journal of Clinical Medicine in Practice, 2025, 29(2): 6-13. DOI: 10.7619/jcmp.20245014
[2]	MOU Yanhui, CHEN Zhaogui, YAO Guang, CHEN Jingci, QUAN Zhi. Mechanism of acupuncture on hippocampal neuron apoptosis in rat model of post-traumatic stress disorder via the reactive oxygen species/c-Jun N-terminal kinase/p53 pathway[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 44-49, 72. DOI: 10.7619/jcmp.20243510
[3]	CUI Xiaojing, ZHAO Chunmei, YANG Bo. Expression and significance of serum insulin-like growth factor binding protein-7 and silencing information regulator 4 in patients with acute heart failure[J]. Journal of Clinical Medicine in Practice, 2024, 28(3): 74-78, 83. DOI: 10.7619/jcmp.20232118
[4]	YANG Ting, WANG Xiaohong, LI Yi. The clinical efficacy and mechanism of melatonin in the treatment of premature ovarian insufficiency[J]. Journal of Clinical Medicine in Practice, 2023, 27(16): 75-78, 83. DOI: 10.7619/jcmp.20230708
[5]	LI Ning, WU Feng, HU Tao. Research progress of hypoxia-inducible factor-1α and obstructive sleep apnea associated hypertension[J]. Journal of Clinical Medicine in Practice, 2023, 27(7): 138-142. DOI: 10.7619/jcmp.20223407
[6]	LIAO Weizu, JIA Gengpei, YANG Zheng, SUN Yi. Effect and mechanism of oxyhydrogen machine in antifungal adjuvant therapy[J]. Journal of Clinical Medicine in Practice, 2022, 26(20): 16-22. DOI: 10.7619/jcmp.20221558
[7]	PENG Yuan, SHENG Xiao, YE Xinhua, YU Wenlong, XUE Yun, CHENG Jinluo. High glucose stimulates oxidative stress and inflammatory response of glomerular mesangial cells in rats by regulating PINK1/Parkin pathway[J]. Journal of Clinical Medicine in Practice, 2021, 25(20): 6-12. DOI: 10.7619/jcmp.20212562
[8]	XU Lei, YANG Lei, WU Fan, YAN Ying, HANG Xiao, YU Duonan. MiR-144/451 suppresses AKT phosphorylation by controlling ROS levels in erythroid cells of rats: A clinical trail study[J]. Journal of Clinical Medicine in Practice, 2020, 24(2): 29-32. DOI: 10.7619/jcmp.202002009
[9]	ZHANG Rong, YANG Xinquan, XIONG Ting, TANG Shan, AI Keqing, ZHONG Hongyan, MAO Yongqing, WANG Daxin. GKT137831 alleviates atorvastatin-induced decreased glucose uptake of skeletal muscle by suppressing reactive oxygen species level[J]. Journal of Clinical Medicine in Practice, 2019, 23(10): 53-57. DOI: 10.7619/jcmp.201910015
[10]	LIANG Yefei, ZHOU Youwang. Effects of an oxygen free radical scavenger on serum inflammatory factors of patients with acute cerebral hemorrhage[J]. Journal of Clinical Medicine in Practice, 2013, (14): 53-55. DOI: 10.7619/jcmp.201314018

Cited By

Get Citation

PDF

XML

Article views (563) PDF downloads (46)

Turn off MathJax

Article Contents

Abstract

References

Research progress of gastric intestinal metaplasia

Abstract

References

Related Articles

Catalog

Research progress of gastric intestinal metaplasia

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content